Aveva Drug Delivery systems has announced the launch of all strengths of its generic Fentanyl Transdermal Patch in the US market.

The launch of Fentanyl TDS, a prescription 3-day transdermal patch for managing moderate to severe chronic pain (generic equivalent to Duragesic®), required the rapid sourcing and seamless integration of advanced manufacturing equipment's with existing systems to meet regulatory and operational standards.

The Fentanyl TDS patch with reported US sales of USD 182 Mn is an extended-release opioid analgesic intended for around-the-clock pain management in patients who require long-term opioid treatment.

Commenting on this launch, Ramandeep Singh Jaj, Founder and Co-CEO of DifGen Pharmaceuticals commented, "Chronic pain significantly impacts quality of life. Our goal is to provide patients and healthcare providers with effective, reliable options for this essential pain management product, that can eliminate consistent supply disruptions leading to cyclical shortages that can place undue burden on the US Healthcare system".

Commenting on the significant challenges associated with this product and the need to mitigate potential abuse of opioid medications, Dr. Santhanakrishnan Srinivasan, Founder and Co-CEO of DifGen Pharmaceuticals commented, "With a matrix-based technology, our patch is designed to deter abuse and provide consistent and effective relief for patients suffering from chronic pain. The product, available in eight strengths ranging from 12.5mcg to 100mcg to allow for tailored pain management, is built on an adhesive technology designed for comfort and durability and developed with a tamper evident design to support responsible opioid use"

The intricate process developed by Aveva DDS ensures that the patches are consistently produced to meet strict safety, efficacy, and compliance standards.